Results 51 to 60 of about 198,722 (342)

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources

Melanoma BRAF Fusions—Response [PDF]

Clinical Cancer Research, 2014
We appreciate the comments from Dr. Botton and colleagues ([1][1]) regarding our article entitled “BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition” ([2][2]). In response to their letter, we make the following points: 1.
Katherine E, Hutchinson, Jeffrey S, Ross, Philip J, Stephens, Vincent A, Miller, Jeffrey A, Sosman, William, Pao   +5 more
openaire   +2 more sources

Comparative study between Immunohistochemistry and Molecular method in detection of BRAF V600E mutation in papillary thyroid carcinoma

Basrah Journal of Surgery, 2023
Background Papillary thyroid carcinoma is the most common endocrine and thyroid malignancy. The (BRAF V600E) mutation is the most common mutation in papillary thyroid cancer (PTC). The mutation is detected in about (60%) of the cases.
Sarah Ali Darweesh, Jasim M. Al-Diab, Sawsan S. Al-Harron, Hussam Aziz Hasson   +3 more
doaj   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

Сибирский онкологический журнал, 2020
Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov, V. M. Safronova, S. N. Nered, L. N. Lyubchenko, I. S. Stilidi   +4 more
doaj   +1 more source

PIK3CA mutations in advanced cancers: characteristics and outcomes. [PDF]

, 2012
PIK3CA mutations are frequently diagnosed in diverse cancers and may predict response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are associated with other characteristics.
Falchook, Gerald S, Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S, Janku, Filip, Kurzrock, Razelle, Lee, Jack J, Luthra, Rajyalakshmi, Moulder, Stacy L, Naing, Aung, Piha-Paul, Sarina A, Stepanek, Vanda M, Tsimberidou, Apostolia M, Wheler, Jennifer J   +13 more
core   +4 more sources

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

Journal of Thoracic Oncology, 2020
INTRODUCTION Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated.
F. Guisier, C. Dubos-Arvis, F. Viñas, H. Doubre, C. Ricordel, S. Ropert, H. Janicot, M. Bernardi, P. Fournel, R. Lamy, M. Pérol, J. Dauba, Gilles Gonzales, L. Falchero, C. Decroisette, P. Assouline, C. Chouaid, O. Bylicki   +17 more
semanticscholar   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review

Journal of Clinical Medicine, 2023
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients.
Wajeeha Aiman, Muhammad Ashar Ali, Samer Jumean, Ummul Asfeen, Jose Garcia, Murad Quirem, Amaar Ahmad, Mohammad Nabil Rayad, Osama Alkhlaifat, Bader Al Omour, Venkata S. Chemarthi, Michael Maroules, Gunwant Guron, Hamid Shaaban   +13 more
openaire   +2 more sources